Answers are grounded in this paper and cite their sources.
Using biomarker test results from a patient’s medical record or testing by a local clinical site can accelerate trial enrollment when compared with using a trial sponsor’s clinical trial assay or candidate companion diagnostic provided by central laboratories. However, doing so may create technical, operational, and regulatory complexities for sponsors. A risk-based framework can inform sponsor decisions and awareness of risks and benefits as interest in using local tests increases.
No takes yet. Share an insight, caveat, or question.
Shaughnessy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: